RCM
RIGL icon

Raleigh Capital Management’s Rigel Pharmaceuticals RIGL Stock Holding History

Raleigh Capital Management’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-141
Closed -$2.05K – 1142
2023
Q4 		$2.05K Buy
+141
New +$1.44K ﹤0.01% 864

Other funds holding RIGL

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Raleigh Capital Management's RIGL Position: Q1 2024 in Review

Raleigh Capital Management sold out of Rigel Pharmaceuticals (RIGL) in Q1 2024, closing a stake of 141 shares — an estimated $2.05K sold.

Raleigh Capital Management first reported a position in RIGL in Q4 2023 and held it in 1 quarter. The position peaked at $2.05K in Q4 2023. 117 funds tracked by Wall St. Rank hold RIGL as of Q1 2024.

  • Raleigh Capital Management reported no remaining Rigel Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Raleigh Capital Management sold 141 Rigel Pharmaceuticals shares in Q1 2024, an estimated $2.05K.
  • Raleigh Capital Management first reported a position in Rigel Pharmaceuticals in Q4 2023 and held it in 1 quarter.
  • Raleigh Capital Management's Rigel Pharmaceuticals position peaked at $2.05K in Q4 2023.
  • 117 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2024.

Based on Raleigh Capital Management's 13F filing for Q1 2024, filed 13 May 2024.